ライフサイエンスコーパス: nonsteroidal

1 ion, we have identified for the first time a nonsteroidal agent that selectively activates beta1-cont

2 Whether exogenous nonsteroidal agents can access this site to selectively

3 gimens in patients with prior sensitivity to nonsteroidal AI and in baseline plasma from the PALOMA3

4 MBC whose disease progresses while receiving nonsteroidal AIs.

5 Treatment of bone pain includes nonsteroidal analgesics and opiates; however, long-term

6 A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benz

7 d crystal structure of the GR LBD bound to a nonsteroidal antagonist, and this article provides addit

8 igand-binding domain (GR LBD) complex with a nonsteroidal antagonist, compound 8, was determined.

9 d intracellular CYP450 on the removal of six nonsteroidal anti-inflammatories (NSAIs) by Trametes hir

10 drugs in five different classes (uricosuric, nonsteroidal anti-inflammatories, loop diuretics, angiot

11 Scleritis resolved with oral nonsteroidal anti-inflammatory agent alone in 1 patient

12 anti-inflammatory activity compared with the nonsteroidal anti-inflammatory agent ketorolac.

13 h (45 mg/kg) dose of HCT 1026, a NO-donating nonsteroidal anti-inflammatory agent which has previousl

14 ly symptomatic osteoarthritis managed with a nonsteroidal anti-inflammatory agent.

15 the synthesis of azo mutual prodrugs of the nonsteroidal anti-inflammatory agents (NSAIDs) 4-aminoph

16 k have often included patients using aspirin/nonsteroidal anti-inflammatory agents (NSAIDs) or acid-s

17 Nonsteroidal anti-inflammatory agents are not associated

18 rvations: Regional analgesia, acetaminophen, nonsteroidal anti-inflammatory agents, gabapentinoids, t

19 aration, as demonstrated by synthesis of the nonsteroidal anti-inflammatory diflunisal.

20 Inhibition of PGE2 production through nonsteroidal anti-inflammatory drug (NSAID) administrati

21 Nonsteroidal anti-inflammatory drug (NSAID) exacerbated

22 Diclofenac sodium is a widely used nonsteroidal anti-inflammatory drug (NSAID) for relief o

23 en single nucleotide polymorphisms (SNPs) in nonsteroidal anti-inflammatory drug (NSAID) metabolism a

24 al prednisolone acetate (PA) alone or with a nonsteroidal anti-inflammatory drug (NSAID) or intraoper

25 ng body of evidence links certain aspects of nonsteroidal anti-inflammatory drug (NSAID) pharmacology

26 s between the microbiota and indomethacin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibit

27 l trials have showed no relationship between nonsteroidal anti-inflammatory drug (NSAID) use and AD.

28 ty analyses by repeating the analyses in non-nonsteroidal anti-inflammatory drug (NSAID) users (n = 3

29 (II)-phenanthroline complexes containing the nonsteroidal anti-inflammatory drug (NSAID), indomethaci

30 This study demonstrates that daily use of a nonsteroidal anti-inflammatory drug (NSAID), which inhib

31 Nonsteroidal anti-inflammatory drug (NSAID)-induced urti

32 and anticancer evaluation of novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID) hybrid mo

33 large effusion or tamponade, and failure of nonsteroidal anti-inflammatory drug [NSAID] treatment) i

34 idence of risk transformation during chronic nonsteroidal anti-inflammatory drug administration, this

35 This approach was employed to prepare a nonsteroidal anti-inflammatory drug analogue.

36 In the present study, we identify the nonsteroidal anti-inflammatory drug carprofen as a multi

37 anticancer drug CPT-11 (irinotecan) and the nonsteroidal anti-inflammatory drug diclofenac, it has b

38 K3 channels (A237T) or by application of the nonsteroidal anti-inflammatory drug flufenamic acid (FFA

39 the fragrance component celestolide and the nonsteroidal anti-inflammatory drug ibuprofen, are descr

40 identified a context-dependent effect of the nonsteroidal anti-inflammatory drug indomethacin (IND) o

41 Diclofenac, a nonsteroidal anti-inflammatory drug inhibiting COX-2, in

42 Baseline and nonsteroidal anti-inflammatory drug reaction clinical da

43 yl]amino}pyridine-3-carboxylic acid (NFA), a nonsteroidal anti-inflammatory drug that blocks cyclooxy

44 Nonsteroidal anti-inflammatory drug therapy was effectiv

45 ition and systemic vascular dysfunction with nonsteroidal anti-inflammatory drug usage.

46 r measured risk factor, including aspirin or nonsteroidal anti-inflammatory drug use (3.0% and 3.1%,

47 s and the 2007 recommendation on aspirin and nonsteroidal anti-inflammatory drug use to prevent color

48 mass index, height, smoking status, aspirin/nonsteroidal anti-inflammatory drug use, alcohol use, an

49 ching yielded 6,088 statin user pairs, 2,886 nonsteroidal anti-inflammatory drug user pairs, 1,440 gl

50 r statin users, 1.00 (95% CI, 0.90-1.11) for nonsteroidal anti-inflammatory drug users, 0.97 (95% CI,

51 statin users, 21.3% (95% CI, 19.8-22.9%) for nonsteroidal anti-inflammatory drug users, 17.4% (95% CI

52 rized, nonsteroidal anti-inflammatory drugs (nonsteroidal anti-inflammatory drug), R-flurbiprofen and

53 ation and distribution of ibuprofen, a model nonsteroidal anti-inflammatory drug, in a phospholipid b

54 We found that indomethacin, a nonsteroidal anti-inflammatory drug, induced profound an

55 Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is given to prevent

56 ment goals are not met, a trial of a topical nonsteroidal anti-inflammatory drug, tramadol, or both i

57 Nonsteroidal anti-inflammatory drug-activated gene-1 (NA

58 Some manifestations, such as nonsteroidal anti-inflammatory drug-associated angioedem

59 , indicating that second generation GSMs and nonsteroidal anti-inflammatory drug-based GSMs have diff

60 uished: NSAID-exacerbated cutaneous disease, nonsteroidal anti-inflammatory drug-induced urticaria/an

61 Treatment with a potent non-nonsteroidal anti-inflammatory druglike GSM revealed a n

62 scle relaxants, latex and anesthetics (15%), nonsteroidal anti-inflammatory drugs (10.2%), acetaminop

63 4.81-5.64), steroids (3.18; 2.99-3.39), and nonsteroidal anti-inflammatory drugs (2.37; 2.26-2.48) w

64 ocal anesthesia (31.1% vs 12.9%; P < 0.001), nonsteroidal anti-inflammatory drugs (33.5% vs 14.4%; P

65 rent use of antihypertensive medications and nonsteroidal anti-inflammatory drugs (adjusted odds rati

66 es of a new series of nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NO-NSAIDs) possess

67 Interestingly, two well characterized, nonsteroidal anti-inflammatory drugs (nonsteroidal anti-

68 hted associations between the regular use of nonsteroidal anti-inflammatory drugs (NSAID) and reduced

69 Nonsteroidal anti-inflammatory drugs (NSAID) exhibit ant

70 tions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake.

71 or alcohol consumption, co-administration of nonsteroidal anti-inflammatory drugs (NSAID) or concomit

72 mide antibiotics (7.4%), opiates (6.8%), and nonsteroidal anti-inflammatory drugs (NSAIDs) (3.5%).

73 19), NAR against aspirin (n = 12) and other nonsteroidal anti-inflammatory drugs (NSAIDs) (n = 8), a

74 ere included: 10 trials evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (n=4,258)

75 the potential chemopreventive properties of nonsteroidal anti-inflammatory drugs (NSAIDs) against me

76 ing acute or chronic pains or inflammations, nonsteroidal anti-inflammatory drugs (NSAIDs) also assoc

77 sociations of over-the-counter analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) and incide

78 Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-do

79 ween cutaneous melanoma (CM) and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) and statin

80 Nonsteroidal anti-inflammatory drugs (NSAIDs) are among

81 Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) are anti-i

82 Nonsteroidal anti-inflammatory drugs (NSAIDs) are assume

83 For treatment of malignant pleural effusion, nonsteroidal anti-inflammatory drugs (NSAIDs) are avoide

84 Nonsteroidal anti-inflammatory drugs (NSAIDs) are effect

85 Nonsteroidal anti-inflammatory drugs (NSAIDs) are effica

86 lusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) are sparse

87 Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mo

88 Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mo

89 related anaphylaxis induced by LTPs requires nonsteroidal anti-inflammatory drugs (NSAIDs) as a trigg

90 Are nonsteroidal anti-inflammatory drugs (NSAIDs) associated

91 Clinical Question: Are nonsteroidal anti-inflammatory drugs (NSAIDs) associated

92 Are topical nonsteroidal anti-inflammatory drugs (NSAIDs) associated

93 Nonsteroidal anti-inflammatory drugs (NSAIDs) can damage

94 Nonsteroidal anti-inflammatory drugs (NSAIDs) cause bron

95 to aspirin (acetylsalicylic acid) and other nonsteroidal anti-inflammatory drugs (NSAIDs) constitute

96 Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) contribute

97 infarction (MI); however, concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) could pose

98 ast cancer would benefit from treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) during pos

99 ynthesis of prostanoids, various widely used nonsteroidal anti-inflammatory drugs (NSAIDs) enhance en

100 drugs such as acetaminophen/paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) for mild c

101 Regular use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been r

102 Certain rapid reversible, competitive nonsteroidal anti-inflammatory drugs (NSAIDs) have been

103 Nonsteroidal anti-inflammatory drugs (NSAIDs) have many

104 Nonsteroidal anti-inflammatory drugs (NSAIDS) have recei

105 Structural modifications of nonsteroidal anti-inflammatory drugs (NSAIDs) have succe

106 Few studies investigated hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) in childre

107 enefit the most from using aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in relatio

108 Ion-exchange removal of nonsteroidal anti-inflammatory drugs (NSAIDs) in synthet

109 Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associa

110 suggested that there is a mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) may interf

111 We sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on T-cell

112 escribe the effect of routine use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on the inc

113 s document for hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) proposed b

114 Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protect ag

115 logical studies indicate that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces th

116 ND & AIMS: Use of aspirin and/or non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) reduces th

117 Topical nonsteroidal anti-inflammatory drugs (NSAIDs) significan

118 Targeting of COX-1/2 using nonsteroidal anti-inflammatory drugs (NSAIDs) such as th

119 The ability of nonsteroidal anti-inflammatory drugs (NSAIDs) to inhibit

120 d that acute respiratory infection (ARI) and nonsteroidal anti-inflammatory drugs (NSAIDs) use could

121 he cardiovascular risk associated with using nonsteroidal anti-inflammatory drugs (NSAIDs) was associ

122 Topical steroids and oral nonsteroidal anti-inflammatory drugs (NSAIDs) were used

123 ials evaluating the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) when used

124 e associations between use of aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and aceta

125 e placebo-controlled) shows that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corti

126 e placebo-controlled) shows that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corti

127 e of proton pump inhibitors (PPIs), aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selec

128 Oxicams are widely used nonsteroidal anti-inflammatory drugs (NSAIDs), but littl

129 ribute to enteropathy associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs), but there

130 g modes to equine serum albumin (ESA) of two nonsteroidal anti-inflammatory drugs (NSAIDs), diclofena

131 eview the recent literature on the safety of nonsteroidal anti-inflammatory drugs (NSAIDs), glucocort

132 Nonsteroidal anti-inflammatory drugs (NSAIDs), including

133 ends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchi

134 Successful treatment response to nonsteroidal anti-inflammatory drugs (NSAIDs), steroidal

135 ve been evaluated for prophylaxis, including nonsteroidal anti-inflammatory drugs (NSAIDs), which are

136 arin with antiplatelet drugs or nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), which fur

137 nisms different from those of agents such as nonsteroidal anti-inflammatory drugs (NSAIDs).

138 PG biosynthesis is inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs).

139 ith acute sinusitis compared with placebo or nonsteroidal anti-inflammatory drugs (NSAIDs)?

140 mma-secretase modulators (GSMs), such as the nonsteroidal anti-inflammatory drugs (R)-flurbiprofen an

141 cantly decrease risks for SP included use of nonsteroidal anti-inflammatory drugs (RR, 0.77; 95% CI,

142 antihypertensives, 4 diabetes medications, 2 nonsteroidal anti-inflammatory drugs [NSAIDs] or aspirin

143 hort-term exposure to SSRIs, as is done with nonsteroidal anti-inflammatory drugs and aspirin.

144 oxide H synthases are targets of nonspecific nonsteroidal anti-inflammatory drugs and COX-2-specific

145 Accordingly, nonsteroidal anti-inflammatory drugs and NADPH oxidase i

146 treated with potassium-sparing diuretics or nonsteroidal anti-inflammatory drugs and oral potassium

147 laxis against post-ERCP pancreatitis such as nonsteroidal anti-inflammatory drugs and secretin, there

148 eful and reduce side effects associated with nonsteroidal anti-inflammatory drugs and selective cyclo

149 aged 65 years or older, lack of exposure to nonsteroidal anti-inflammatory drugs and statins.

150 providing access to a variety of enantiopure nonsteroidal anti-inflammatory drugs and to alpha-amino

151 Low-molecular-weight heparin and nonsteroidal anti-inflammatory drugs are associated with

152 inflammation, and the beneficial actions of nonsteroidal anti-inflammatory drugs are attributed to i

153 Oral nonsteroidal anti-inflammatory drugs are not recommended

154 analgesic, and anti-inflammatory drugs, such nonsteroidal anti-inflammatory drugs are used in the tre

155 should consider pharmacologic treatment with nonsteroidal anti-inflammatory drugs as first-line thera

156 employment status, and use of analgesics and nonsteroidal anti-inflammatory drugs at 1 and 12 months.

157 r array is able to differentiate six typical nonsteroidal anti-inflammatory drugs at concentrations o

158 ted in the effluent exposome of fish, 6 were nonsteroidal anti-inflammatory drugs but with plasma con

159 A recent meta-analysis suggests that all nonsteroidal anti-inflammatory drugs confer some cardiov

160 hen was ineffective for acute low back pain, nonsteroidal anti-inflammatory drugs had smaller benefit

161 rmance in semiquantitative identification of nonsteroidal anti-inflammatory drugs has been investigat

162 trials (RCTs) showed that oral steroids and nonsteroidal anti-inflammatory drugs have similar analge

163 tended to arylpropionic acids (including the nonsteroidal anti-inflammatory drugs ibuprofen and flurb

164 advances in our understanding of the role of nonsteroidal anti-inflammatory drugs in CRC prevention a

165 Reactions to aspirin and nonsteroidal anti-inflammatory drugs in patients with as

166 dence of tumors in individuals who have used nonsteroidal anti-inflammatory drugs is supportive of a

167 Nonsteroidal anti-inflammatory drugs may impair wound he

168 BACKGROUND& AIMS: Proton pump inhibitors and nonsteroidal anti-inflammatory drugs might prevent esoph

169 BF4)3 and [Ru(NH3)5(L)](BF4)3 containing the nonsteroidal anti-inflammatory drugs nicotinic acid (Hni

170 (HR, 0.68; 95% CI, 0.53-0.87; P = .002), and nonsteroidal anti-inflammatory drugs or aspirin use (HR,

171 sired, clinicians and patients should select nonsteroidal anti-inflammatory drugs or skeletal muscle

172 lls with pharmacological inhibitors, such as nonsteroidal anti-inflammatory drugs or small interferin

173 ts include oral contraceptives combined with nonsteroidal anti-inflammatory drugs or surgery to remov

174 ctures (OR, 2.65; 95% CI, 2.34-2.99), use of nonsteroidal anti-inflammatory drugs plus opioids (OR, 1

175 PCME prophylaxis with topical nonsteroidal anti-inflammatory drugs remains unproven be

176 Placebo-controlled trials of nonsteroidal anti-inflammatory drugs selective for inhib

177 to cause cardiovascular adverse effects than nonsteroidal anti-inflammatory drugs specific for inhibi

178 Nonsteroidal anti-inflammatory drugs such as sulindac in

179 Nonsteroidal anti-inflammatory drugs use during ARI epis

180 Nonsteroidal anti-inflammatory drugs use during ARI was

181 Subjects with asthma hypersensitive to nonsteroidal anti-inflammatory drugs were compared with

182 Eyes receiving prophylactic nonsteroidal anti-inflammatory drugs were excluded.

183 rt A) or unspecified (cohort B) reactions to nonsteroidal anti-inflammatory drugs were identified as

184 , decreased hematocrit, aspirin therapy, and nonsteroidal anti-inflammatory drugs were independently

185 UV filters, personal sunscreen products, and nonsteroidal anti-inflammatory drugs were seen in both g

186 hese differential effects were ignored, oral nonsteroidal anti-inflammatory drugs were superior.

187 lofenac is one of the most widely prescribed nonsteroidal anti-inflammatory drugs worldwide.

188 (age, sex, smoking, body mass index, use of nonsteroidal anti-inflammatory drugs) and symptoms of ga

189 ions (statins, aspirin, corticosteroids, and nonsteroidal anti-inflammatory drugs), with ulcerated pr

190 ry reactions to cyclooxygenase-1 inhibitors (nonsteroidal anti-inflammatory drugs).

191 g unnecessary medications such as aspirin or nonsteroidal anti-inflammatory drugs).

192 rials ranged from 9 (benzodiazepines) to 70 (nonsteroidal anti-inflammatory drugs).

193 These patients are usually treated with nonsteroidal anti-inflammatory drugs, acetaminophen, opi

194 ere found for coffee drinking, hypertension, nonsteroidal anti-inflammatory drugs, calcium channel bl

195 other antihypertensives, aspirin, steroids, nonsteroidal anti-inflammatory drugs, Charlson Comorbidi

196 cancer associations were observed by use of nonsteroidal anti-inflammatory drugs, cigarette smoking,

197 is inhibited by ACA as well as the fenamate nonsteroidal anti-inflammatory drugs, flufenamate and ni

198 Preadmission use of statins, nonsteroidal anti-inflammatory drugs, glucocorticoids, o

199 igarette smoking, obesity, no regular use of nonsteroidal anti-inflammatory drugs, high intake of red

200 casionally after the intake of drugs such as nonsteroidal anti-inflammatory drugs, opioids and drugs

201 h DILI (due to acetaminophen, phenprocoumon, nonsteroidal anti-inflammatory drugs, or autoimmune hepa

202 ion single-agent or combined use of statins, nonsteroidal anti-inflammatory drugs, or glucocorticoids

203 Intra-articular treatments were superior to nonsteroidal anti-inflammatory drugs, possibly because o

204 For the target COX-2 of nonsteroidal anti-inflammatory drugs, SPA successfully d

205 h-sensitivity C-reactive protein, and use of nonsteroidal anti-inflammatory drugs, statins, and multi

206 acting on the brain and can be prevented by nonsteroidal anti-inflammatory drugs, such as aspirin or

207 Nonsteroidal anti-inflammatory drugs-induced urticaria/a

208 esult from the now worldwide availability of nonsteroidal anti-inflammatory drugs.

209 iguanides, sulfonylureas, aspirin, and other nonsteroidal anti-inflammatory drugs.

210 arallel samples were stimulated with related nonsteroidal anti-inflammatory drugs.

211 ion, and prophylaxis against ulceration from nonsteroidal anti-inflammatory drugs.

212 dified by factors such as smoking and use of nonsteroidal anti-inflammatory drugs.

213 unds, such as gamma-secretase inhibitors and nonsteroidal anti-inflammatory drugs.

214 o resistant to gamma-secretase modulation by nonsteroidal anti-inflammatory drugs.

215 implicates a potential therapeutic role for nonsteroidal anti-inflammatory drugs.

216 r warfarin, and 0.51 (95% CI, 0.34-0.78) for nonsteroidal anti-inflammatory drugs.

217 with short courses of oral contraceptives or nonsteroidal anti-inflammatory drugs.

218 mPGES-1 inhibitors as a safe alternative to nonsteroidal anti-inflammatory drugs.

219 so demonstrates the synthesis of a number of nonsteroidal anti-inflammatory drugs.

220 vity reactions to beta-lactams, aspirin, and nonsteroidal anti-inflammatory drugs; however, the clini

221 that was not responsive to over-the-counter nonsteroidal anti-inflammatory medications.

222 ation of two therapeutic drugs, benzydamine (nonsteroidal anti-inflammatory) and tamoxifen (antiestro

223 Bicalutamide, a nonsteroidal antiandrogen, is widely used to treat men w

224 tion of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of sm

225 Most of the commercially available nonsteroidal antiandrogens show a common scaffold consis

226 logically active substances (antibacterials, nonsteroidal antiinflammatories, antiseptics, antiepilep

227 The present study compared the effect of the nonsteroidal antiinflammatory drug (NSAID) diclofenac, w

228 The authors conducted a cohort study of nonsteroidal antiinflammatory drug (NSAID) use and risk

229 In the present study, sulindac, a nonsteroidal antiinflammatory drug (NSAID), was tested f

230 indings are potentially game-changing in the nonsteroidal antiinflammatory drug arena.

231 3 effects to blockade by two analgesics (the nonsteroidal antiinflammatory drug ketoprofen and the mu

232 epidemiological studies have shown that the nonsteroidal antiinflammatory drug naproxen may be usefu

233 Aspirin, nonsteroidal antiinflammatory drugs (NSAID), and acetami

234 Among nonusers of nonsteroidal antiinflammatory drugs (NSAIDs) (Pinteracti

235 e cancer and whether use of aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) affects ris

236 ntrol studies have shown that regular use of nonsteroidal antiinflammatory drugs (NSAIDs) decreases b

237 Although nonsteroidal antiinflammatory drugs (NSAIDs) in general

238 The cardiovascular safety of nonsteroidal antiinflammatory drugs (NSAIDs) may be infl

239 (LUTS), raising the possibility that use of nonsteroidal antiinflammatory drugs (NSAIDs) may inhibit

240 of nine measures of high-risk prescribing of nonsteroidal antiinflammatory drugs (NSAIDs) or selected

241 Acid suppression, nonsteroidal antiinflammatory drugs (NSAIDs), and statin

242 of celecoxib, as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains un

243 nd is the therapeutic target for widely used nonsteroidal antiinflammatory drugs (NSAIDs).

244 atechins (naturally occurring flavonols) and nonsteroidal antiinflammatory drugs (NSAIDs).

245 n of >/=6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids)

246 research suggests that rectally administered nonsteroidal antiinflammatory drugs may reduce the incid

247 rgery, 55% of patients received prescription nonsteroidal antiinflammatory drugs, 58% received opioid

248 Nonsteroidal antiinflammatory drugs, including ibuprofen

249 gs that are widely used to treat OA, such as nonsteroidal antiinflammatory drugs, may have limited ef

250 d arthritis (RA) and its response to chronic nonsteroidal antiinflammatory drugs.

251 looxygenase 2 inhibitors versus nonselective nonsteroidal antiinflammatory medications in 6-month gas

252 Interestingly, we now identified a nonsteroidal antiinflammatory selective GR agonist (SEGR

253 t elements of the cardiovascular hazard from nonsteroidal antinflammatory drugs (NSAIDs).

254 e small chemical changes in the structure of nonsteroidal AR ligands determine the pharmacological re

255 er experiencing recurrence/progression after nonsteroidal aromatase inhibitor (AI) therapy.

256 sion while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting

257 ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor were randomly assigned

258 se inhibitor; AvodartTM); (d) T + Letrozole (nonsteroidal aromatase inhibitor; FemeraTM); (e) Flutami

259 ard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letroz

260 estane is partially non-cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen

261 vanced breast cancer previously treated with nonsteroidal aromatase inhibitors.

262 This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neit

263 Analogies to recent developments in nonsteroidal conjugates targeting AR are also evaluated.

264 ent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through mic

265 methyl group was designed and synthesized as nonsteroidal CYP19 aromatase inhibitors.

266 Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer p

267 rapeutic agents (nonparticulate steroids and nonsteroidal drugs alike).

268 ver some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical

269 Researchers have developed nonsteroidal ecdysteroid agonists for EcR that disrupt m

270 e-activity relationship (SAR) of a series of nonsteroidal glucocorticoid receptor (GR) agonists are d

271 Seven-day treatment with inhalation of the nonsteroidal glucocorticoid receptor agonist AZD5423 eff

272 We evaluated the effect of an inhaled nonsteroidal glucocorticoid receptor agonist, AZD5423, o

273 ta[h]quinolin-3-one 3d (QCA-1093) as a novel nonsteroidal glucocorticoid receptor antagonist.

274 prednisolone and also by compound A, a novel nonsteroidal glucocorticoid receptor ligand.

275 sonicotinamides exemplified by compound 3 as nonsteroidal GPBAR1 agonists.

276 sign and pharmacology of clinically relevant nonsteroidal GR antagonists that may have greater select

277 refined classic GCs or a novel generation of nonsteroidal GR-targeting molecules, to meet the increas

278 vidence for the successful implementation of nonsteroidal inflammatory mediators in IOI is accumulati

279 f the cardioactive terpenoid (+)-cassaine, a nonsteroidal inhibitor of Na(+)-K(+)-ATPase.

280 exes with estrone and with the first potent, nonsteroidal inhibitor.

281 dy was to identify and optimize 17beta-HSD14 nonsteroidal inhibitors as well as to disclose their str

282 ated whether the administration of the novel nonsteroidal mineralocorticoid receptor (MR) antagonist

283 A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists

284 modifications were efficiently prevented by nonsteroidal MR antagonism.

285 s effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher t

286 restricted to steroidal MR antagonists as a nonsteroidal MR antagonist failed to reduced blood press

287 MR blockade by the novel nonsteroidal MR antagonist, finerenone, or genetic delet

288 Finerenone, a novel nonsteroidal MR antagonist, is presently being evaluated

289 Tanaproget is a nonsteroidal progestin agonist with very high PR binding

290 Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibito

291 However, a more direct, nonsteroidal role of LH mediating the spermiogenic pathw

292 reports have described the increasing use of nonsteroidal selective androgen receptor modulators, whi

293 gic evidence showed that AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and

294 A class of potent, nonsteroidal, selective indazole ether-based glucocortic

295 alpha-trenbolone, 17beta-trenbolone, for the nonsteroidal semisynthetic estrogen agonist, alpha-zeara

296 The LBD responds to classic steroidal and nonsteroidal small ligands; both may selectively modify

297 ification and characterization of AZD9496, a nonsteroidal small-molecule inhibitor of ERalpha, which

298 fundamental need to identify nonestrogen or nonsteroidal targets for the treatment of endometriosis.

299 basis to formulate long-term nonestrogen or nonsteroidal therapy for endometriosis.

300 ctions with developmental proteins and other nonsteroidal transcription factors, drives this tumor ad